Artificial intelligence (AI) software developer Koios Medical is highlighting the results of a study that used its DS Breast 2.0 as a second opinion for analyzing and assessing lesions found during breast ultrasound examinations.
During an 18-month software evaluation period, radiologists at a private practice used Koios' software to assist in lesion classifications and risk assessments of about 6,000 diagnostic breast ultrasound exams. Radiologists would activate Koios DS and review the software findings with clinical details to formulate the best management plan.
The diagnostic performance of the physicians was compared with the 18-month period prior to the introduction of the AI-enabled software. It was determined that physicians recommended biopsy for suspicious lesions at a similar rate of 17% and performed 14% more biopsies, increasing the cancer detection rate while simultaneously experiencing a significant reduction in benign biopsies, according to a press release from Koios.
The aggregate nature of the findings when the company began gradually adopting the software during the evaluation period also was noteworthy. Trailing six-month results indicated a reduction in benign biopsies exceeding 20% across the group. Positive predictive value improved by about 20%, Koios stated.
